Hepatic Encephalopathy: Diagnostic Tools and Management Strategies.
Ammonia
Covert hepatic encephalopathy
Diagnosis
Management
Overt hepatic encephalopathy
Treatments
Journal
The Medical clinics of North America
ISSN: 1557-9859
Titre abrégé: Med Clin North Am
Pays: United States
ID NLM: 2985236R
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
medline:
4
4
2023
entrez:
31
3
2023
pubmed:
1
4
2023
Statut:
ppublish
Résumé
Hepatic encephalopathy (HE) is brain dysfunction secondary to liver insufficiency or portosystemic shunting. HE is a major burden on patients and caregivers, impairs quality of life and is associated with higher mortality. Overt HE is a clinical diagnosis while Covert HE, needs specialized diagnostic strategies. Mainstay of treatment of HE is nonabsorbable disaccharides such as lactulose as well as rifaximin; however, investigational therapies are discussed in this review. Better tools are needed to prognosticate which patients will go on to develop HE but microbiome and metabolomic-driven strategies are promising. Here we review methods to prevent the HE development and admissions.
Identifiants
pubmed: 37001951
pii: S0025-7125(23)00003-2
doi: 10.1016/j.mcna.2023.01.003
pii:
doi:
Substances chimiques
Lactulose
4618-18-2
Rifaximin
L36O5T016N
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-531Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.